Surefire Medical touted data today from a retrospective analysis of 85 bridge-to-transplant liver cancer patients treated with transarterial chemoembolization. The data showed that therapy delivered using the Surefire infusion system yielded an 80% complete response in 1 treatment compared to 52% with a standard endhole microcatheter. The analysis also demonstrated a lower recurrence rate of liver cancer at 1 month for patients that used Surefire's technology instead of a conventional microcatheter. Get the full story at our sister site, Drug Delivery Business News. The post Surefire Medical touts infusion tech in liver cancer trial appeared first on MassDevice. (Source: Mass Device)
MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2sYDXg2
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,